Urinary sulphate excretion and progression of diabetic nephropathy in Type 1 diabetes

Diabetic Medicine

Volumn 30, Issue 5, 2013, Pages 563-566

  Andresdottir G ^a   Bakker, S J L ^b   Hansen, H P ^a,c   Parving, H H ^d,e   Rossing, P ^a,e  

^a STENO DIABETES CENTER   (Denmark)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^d Rigshospitalet   (Denmark)

^e AARHUS UNIVERSITY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

EDETATE CHROMIUM CR 51; HEMOGLOBIN A1C; SULFATE;

ADULT; ALBUMINURIA; ARTICLE; BLOOD PRESSURE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DISEASE COURSE; FEMALE; FOLLOW UP; GENDER; GLOMERULUS FILTRATION RATE; HAZARD RATIO; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; POST HOC ANALYSIS; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; PROTEIN DIET; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SMOKING; URINARY EXCRETION;

ADULT; ALBUMINURIA; BIOLOGICAL MARKERS; DIABETES MELLITUS, TYPE 1; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; PROSPECTIVE STUDIES; RISK FACTORS; SULFITES;

EID: 84876373155     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/dme.12131     Document Type: Article

References (25)

1. Chen L, Ingrid S, Ding YG, Liu Y, Qi JG, Tang CS et al. Imbalance of endogenous homocysteine and hydrogen sulfide metabolic pathway in essential hypertensive children. Chin Med J (Engl) 2007; 120: 389-393.
2. Zhao W, Zhang J, Lu Y, Wang R. The vasorelaxant effect of H(2)S as a novel endogenous gaseous K(ATP) channel opener. EMBO J 2001; 20: 6008-6016.
3. Yang G, Wu L, Jiang B, Yang W, Qi J, Cao K et al. H2S as a physiologic vasorelaxant: hypertension in mice with deletion of cystathionine gamma-lyase. Science 2008; 322: 587-590.
4. Xia M, Chen L, Muh RW, Li PL, Li N. Production and actions of hydrogen sulfide, a novel gaseous bioactive substance, in the kidneys. J Pharmacol Exp Ther 2009; 329: 1056-1062.
5. Beltowski J. Hypoxia in the renal medulla: implications for hydrogen sulfide signaling. J Pharmacol Exp Ther 2010; 334: 358-363.
6. Perna AF, Luciano MG, Ingrosso D, Pulzella P, Sepe I, Lanza D et al. Hydrogen sulphide-generating pathways in haemodialysis patients: a study on relevant metabolites and transcriptional regulation of genes encoding for key enzymes. Nephrol Dial Transplant 2009; 24: 3756-3763.
7. Zavaczki E, Jeney V, Agarwal A, Zarjou A, Oros M, Katko M et al. Hydrogen sulfide inhibits the calcification and osteoblastic differentiation of vascular smooth muscle cells. Kidney Int 2011; 80: 731-739.
8. Brancaleone V, Roviezzo F, Vellecco V, De GL, Bucci M, Cirino G. Biosynthesis of H2S is impaired in non-obese diabetic (NOD) mice. Br J Pharmacol 2008; 155: 673-680.
9. Whiteman M, Gooding KM, Whatmore JL, Ball CI, Mawson D, Skinner K et al. Adiposity is a major determinant of plasma levels of the novel vasodilator hydrogen sulphide. Diabetologia 2010; 53: 1722-1726.
10. Lee HJ, Mariappan MM, Feliers D, Cavaglieri RC, Sataranatarajan K, Abboud HE et al. Hydrogen Sulfide Inhibits High Glucose-induced Matrix Protein Synthesis by Activating AMP-activated Protein Kinase in Renal Epithelial Cells. J Biol Chem 2012; 287: 4451-4461.
11. Yuan P, Xue H, Zhou L, Qu L, Li C, Wang Z et al. Rescue of mesangial cells from high glucose-induced over-proliferation and extracellular matrix secretion by hydrogen sulfide. Nephrol Dial Transplant 2011; 26: 2119-2126.
12. Aminzadeh MA, Vaziri ND. Downregulation of the renal and hepatic hydrogen sulfide (H2S)-producing enzymes and capacity in chronic kidney disease. Nephrol Dial Transplant 2012; 27: 498-504.
13. Nakanishi T, Otaki Y, Hasuike Y, Nanami M, Itahana R, Miyagawa K et al. Association of hyperhomocysteinemia with plasma sulfate and urine sulfate excretion in patients with progressive renal disease. Am J Kidney Dis 2002; 40: 909-915.
14. Sabry ZI, Shadarevian SB, Cowan JW, Campbell JA. Relationship of dietary intake of sulphur amino-acids to urinary excretion of inorganic sulphate in man. Nature 1965; 206: 931-933.
15. Freeman RM, Richards CJ. Studies on sulfate in end-stage renal disease. Kidney Int 1979; 15: 167-175.
16. Hansen HP. Tauber-Lassen E AU - Jensen BR AU - Parving HHAD -Steno Diabetes Center NSV. Effect of dietary protein restriction on prognosis in patients with diabetic nephropathy. Kidney Int 2002; 62: 220-228.
17. Markovich D. Physiological Roles and Regulation of Mammalian Sulfate Transporters. Physiol Rev 2001; 81: 1499-1533.
18. Tallgren LG. Inorganic sulfate in relation to the serum thyroxine level and in renal failure. Acta Med Scand 1980; 640: 1-100.
19. Brunetti M, Terracina L, Timio M, Saronio P, Capodicasa E. Plasma sulfate concentration and hyperhomocysteinemia in hemodialysis patients. J Nephrol 2001; 14: 27-31.
20. Magee EA, Curno R, Edmond LM, Cummings JH. Contribution of dietary protein and inorganic sulfur to urinary sulfate: toward a biomarker of inorganic sulfur intake. Am J Clin Nutr 2004; 80: 137-142.
21. Whiteman M, Moore PK. Hydrogen sulfide and the vasculature: a novel vasculoprotective entity and regulator of nitric oxide bioavailability? J Cell Mol Med 2009; 13: 488-507.
22. Beauchamp RO, Bus JS, Popp JA, Boreiko CJ, Andjelkovich DA, Leber P. A Critical Review of the Literature on Hydrogen Sulfide Toxicity. Crit Rev Toxicol 1984; 13: 25-97.
23. Wang R. Physiological implications of hydrogen sulfide: a whiff exploration that blossomed. Physiol Rev 2012; 92: 791-896.
24. Hildebrandt TM, Grieshaber MK. Three enzymatic activities catalyze the oxidation of sulfide to thiosulfate in mammalian and invertebrate mitochondria. FEBS J 2008; 275: 3352-3361.
25. Kamoun P. Endogenous production of hydrogen sulfide in mammals. Amino Acids 2004; 26: 243-254.